Lobbying Filing Details

Total Spending

$40,000

Activities

3

Lobbyists

3

Gov't Entities

6

Filing Information
Filing UUID:
bac5f3b1-3daf-48cf-80cf-c3dd4ac96fac
Type:
Q1 - 1st Quarter - Report
Period:
2026 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
July 20, 2026 at 8:06 PM
Income:
$40,000
Expenses:
$0
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Alisa Hess
Registrant
ALPINE GROUP PARTNERS, LLC.

Public relations consulting firm

Washington, District of Columbia
Client
ULTRAGENYX PHARMACEUTICAL INC.

Biopharma company developing treatments for rare and ultra-rare diseases.

California, United States of America
Lobbying Activities (3)
Activity 1
Government Issues

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)

Lobbyists (3)
  • KEENAN AUSTIN REED
  • SHAYNE WOODS
  • ERIN MENDELSOHN
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)

Lobbyists (3)
  • KEENAN AUSTIN REED
  • SHAYNE WOODS
  • ERIN MENDELSOHN
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medical/Disease Research/Clinical Labs

Monitoring FDA user fee regulation, including priority review voucher reauthorization; legislation around screening efforts for newborns and ultra-rare diseases likeDuchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD)

Lobbyists (3)
  • KEENAN AUSTIN REED
  • SHAYNE WOODS
  • ERIN MENDELSOHN
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.